Medicare's New Policy Expands Access to Obesity Drugs
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Source: CNBC
- Medicare Coverage Breakthrough: Starting July 1, eligible seniors can access obesity drugs through Medicare's Bridge program for a monthly copay of $50, marking a significant victory for patients and advocates, which is expected to greatly enhance the accessibility of obesity treatments.
- Public Awareness Gap: A survey indicates that 82% of older Americans are unaware of Medicare's upcoming coverage for obesity drugs, which may delay many eligible patients from taking advantage of the new policy, potentially impacting treatment outcomes and health improvements.
- Marketing Strategy Concerns: Despite Novo Nordisk and Eli Lilly's substantial advertising expenditures on obesity drugs, their limited outreach to seniors may hinder awareness and uptake of the new coverage, especially during the initial rollout phase.
- Complex Eligibility Process: Unlike traditional Medicare drug coverage, the Bridge program requires patients to meet specific eligibility criteria and obtain prior authorization, which could create barriers for some patients in accessing timely treatment.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NVO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NVO
Wall Street analysts forecast NVO stock price to rise
8 Analyst Rating
4 Buy
3 Hold
1 Sell
Moderate Buy
Current: 48.070
Low
42.00
Averages
54.67
High
70.00
Current: 48.070
Low
42.00
Averages
54.67
High
70.00
About NVO
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Novo-Nordisk Stock Surpasses Analyst Target Price
- Price Target Surpassed: Novo-Nordisk (NVO) shares recently traded at $48.07, exceeding the average analyst 12-month target price of $47.78, indicating a positive market sentiment towards the company's prospects.
- Diverse Analyst Reactions: Among the 10 analysts covered by Zacks, target prices range from $40.00 to $55.23, with a standard deviation of $5.446, highlighting significant divergence in market expectations regarding the company's future performance.
- Investor Decision Signal: The stock's rise above the target price provides investors with a signal to reassess the company, prompting them to consider whether the current valuation is stretched or if it’s time to take profits to mitigate risk.
- Market Sentiment Analysis: Analyst target prices reflect a
See More
Investment Opportunities in Digital Transformation and Essential Services
- MercadoLibre Market Dominance: MercadoLibre (MELI) dominates e-commerce and financial services across Latin America, with its fintech division, Mercado Pago, providing daily banking and payment services to millions of unbanked consumers, effectively capturing consumer spending in both retail and digital banking.
- Logistics Network Advantage: By controlling the entire system from checkout to doorstep delivery, the company creates an unmatched barrier to entry, and despite aggressive expansion from competitors like Amazon and Shein, its heavy investment in logistics and fulfillment helps solidify its market leadership in Latin America.
- Eli Lilly's Healthcare Transformation: Eli Lilly (LLY) is leading a major healthcare transformation driven by its breakthrough metabolic treatments Mounjaro and Zepbound, with full-year revenue forecasts between $82 billion and $85 billion, significantly expanding its presence in the diabetes and weight loss markets.
- Capacity Expansion: To meet soaring demand, Eli Lilly is pouring $4.5 billion into its Lebanon, Indiana manufacturing facility while actively expanding employer-sponsored coverage to ensure wider access to its GLP-1 medications, and partnering with Oura Ring to help patients track biometric progress.
See More
ADMA Biologics Shows Promising Profitability Outlook
- Profitability Growth: ADMA Biologics reported a net income of $407 million in Q1, reflecting a 22% year-over-year increase, indicating sustained profitability that is expected to enhance the company's competitive edge in the biopharmaceutical market.
- Significant Market Potential: Currently capturing only 4% of its total addressable market, ADMA is positioned for substantial growth, with the market projected to expand at a compound annual growth rate of 10% through 2033, suggesting significant revenue growth opportunities ahead.
- Optimistic Product Outlook: EyePoint Pharmaceuticals is on track to announce results from clinical trials for Duravyu, targeting wet age-related macular degeneration, with a market opportunity exceeding $15 billion, which could significantly elevate the company's market position if approved.
- Investment Risks and Rewards: Viking Therapeutics has an average price target 146% above its current share price, and while it remains unprofitable, its potential in obesity drug development makes it a focal point for investors, despite the inherent investment risks.
See More
MercadoLibre and Eli Lilly's Growth Potential
- Market Dominance of MercadoLibre: MercadoLibre operates a powerful multi-engine system that dominates e-commerce and financial services across Latin America, with its fintech division Mercado Pago providing daily banking and payment services to millions of unbanked consumers, effectively capturing consumer spending and enhancing market competitiveness.
- Logistics Network Advantage: The company controls the entire system from checkout to doorstep delivery, creating an unmatched barrier to entry for international competitors through its extensive proprietary logistics and shipping network, particularly in underpenetrated markets like Brazil and Mexico, further solidifying its market position.
- Healthcare Transformation by Eli Lilly: Eli Lilly is leading a major healthcare transformation driven by its breakthrough metabolic treatments Mounjaro and Zepbound, with full-year revenue forecasts between $82 billion and $85 billion, propelling the company’s growth in the diabetes and weight loss markets.
- Expansion of Production Capacity: To meet soaring demand, Eli Lilly is investing $4.5 billion into its Indiana manufacturing facility and actively expanding employer-sponsored coverage to ensure wider access to its GLP-1 medications, further solidifying its leadership position in the global market.
See More
SpaceX's $2 Trillion Valuation Faces Significant Hurdles Ahead
- SpaceX Valuation Analysis: Despite SpaceX's market cap hovering around $2 trillion, the company generated only $18.7 billion in revenue last year and posted a nearly $5 billion loss, indicating the fragility of its high valuation and making a doubling of its stock price over the next two to three years highly unlikely.
- ADMA Biologics Profit Growth: ADMA Biologics reported a net income of $407 million in Q1, up 22% year-over-year, with its flagship product Asceniv accounting for approximately 86% of total revenue, showcasing strong growth potential in the plasma-derived immunoglobulin market.
- EyePoint Pharmaceuticals Clinical Prospects: EyePoint Pharmaceuticals expects to announce top-line results for Duravyu soon, targeting wet age-related macular degeneration with a market opportunity exceeding $15 billion; analysts are overwhelmingly bullish, with a consensus price target 165% higher than the current share price.
- Viking Therapeutics Potential Breakthrough: Viking Therapeutics is conducting two Phase 3 trials for VK2735, and although it is currently unprofitable, its pipeline includes multiple promising therapies, with the average price target for the stock indicating a potential upside of 146%, reflecting significant growth potential.
See More
Surge in Protein Demand Strains U.S. Dairy Industry
- Dairy Shortages: The USDA reports that U.S. whey protein inventories have fallen by approximately 50% in 2023, leading to shortages among suppliers for the latter half of the year, indicating a tight market supply-demand situation.
- Price Surge: Whey protein isolate prices have reached $14 per pound, reflecting a spike in demand driven by the rising popularity of GLP-1 weight loss drugs, suggesting that protein consumption will continue to rise in the short term.
- Infrastructure Bottlenecks: As whey is a byproduct of cheese production, existing facilities cannot expand quickly, and the approval for additional filtration infrastructure can take years, limiting the supply chain's capacity to grow.
- Market Investment Opportunities: Major dairy companies like Dairy Farmers of America and Saputo are expected to be the first to increase capacity, and while current high prices may moderate in the coming years, it will take time for the market to adjust.
See More
Novo-Nordisk Stock Surpasses Analyst Target Price
- Price Target Surpassed: Novo-Nordisk (NVO) shares recently traded at $48.07, exceeding the average analyst 12-month target price of $47.78, indicating a positive market sentiment towards the company's prospects.
- Diverse Analyst Reactions: Among the 10 analysts covered by Zacks, target prices range from $40.00 to $55.23, with a standard deviation of $5.446, highlighting significant divergence in market expectations regarding the company's future performance.
- Investor Decision Signal: The stock's rise above the target price provides investors with a signal to reassess the company, prompting them to consider whether the current valuation is stretched or if it’s time to take profits to mitigate risk.
- Market Sentiment Analysis: Analyst target prices reflect a
See More
Investment Opportunities in Digital Transformation and Essential Services
- MercadoLibre Market Dominance: MercadoLibre (MELI) dominates e-commerce and financial services across Latin America, with its fintech division, Mercado Pago, providing daily banking and payment services to millions of unbanked consumers, effectively capturing consumer spending in both retail and digital banking.
- Logistics Network Advantage: By controlling the entire system from checkout to doorstep delivery, the company creates an unmatched barrier to entry, and despite aggressive expansion from competitors like Amazon and Shein, its heavy investment in logistics and fulfillment helps solidify its market leadership in Latin America.
- Eli Lilly's Healthcare Transformation: Eli Lilly (LLY) is leading a major healthcare transformation driven by its breakthrough metabolic treatments Mounjaro and Zepbound, with full-year revenue forecasts between $82 billion and $85 billion, significantly expanding its presence in the diabetes and weight loss markets.
- Capacity Expansion: To meet soaring demand, Eli Lilly is pouring $4.5 billion into its Lebanon, Indiana manufacturing facility while actively expanding employer-sponsored coverage to ensure wider access to its GLP-1 medications, and partnering with Oura Ring to help patients track biometric progress.
See More
ADMA Biologics Shows Promising Profitability Outlook
- Profitability Growth: ADMA Biologics reported a net income of $407 million in Q1, reflecting a 22% year-over-year increase, indicating sustained profitability that is expected to enhance the company's competitive edge in the biopharmaceutical market.
- Significant Market Potential: Currently capturing only 4% of its total addressable market, ADMA is positioned for substantial growth, with the market projected to expand at a compound annual growth rate of 10% through 2033, suggesting significant revenue growth opportunities ahead.
- Optimistic Product Outlook: EyePoint Pharmaceuticals is on track to announce results from clinical trials for Duravyu, targeting wet age-related macular degeneration, with a market opportunity exceeding $15 billion, which could significantly elevate the company's market position if approved.
- Investment Risks and Rewards: Viking Therapeutics has an average price target 146% above its current share price, and while it remains unprofitable, its potential in obesity drug development makes it a focal point for investors, despite the inherent investment risks.
See More
MercadoLibre and Eli Lilly's Growth Potential
- Market Dominance of MercadoLibre: MercadoLibre operates a powerful multi-engine system that dominates e-commerce and financial services across Latin America, with its fintech division Mercado Pago providing daily banking and payment services to millions of unbanked consumers, effectively capturing consumer spending and enhancing market competitiveness.
- Logistics Network Advantage: The company controls the entire system from checkout to doorstep delivery, creating an unmatched barrier to entry for international competitors through its extensive proprietary logistics and shipping network, particularly in underpenetrated markets like Brazil and Mexico, further solidifying its market position.
- Healthcare Transformation by Eli Lilly: Eli Lilly is leading a major healthcare transformation driven by its breakthrough metabolic treatments Mounjaro and Zepbound, with full-year revenue forecasts between $82 billion and $85 billion, propelling the company’s growth in the diabetes and weight loss markets.
- Expansion of Production Capacity: To meet soaring demand, Eli Lilly is investing $4.5 billion into its Indiana manufacturing facility and actively expanding employer-sponsored coverage to ensure wider access to its GLP-1 medications, further solidifying its leadership position in the global market.
See More
SpaceX's $2 Trillion Valuation Faces Significant Hurdles Ahead
- SpaceX Valuation Analysis: Despite SpaceX's market cap hovering around $2 trillion, the company generated only $18.7 billion in revenue last year and posted a nearly $5 billion loss, indicating the fragility of its high valuation and making a doubling of its stock price over the next two to three years highly unlikely.
- ADMA Biologics Profit Growth: ADMA Biologics reported a net income of $407 million in Q1, up 22% year-over-year, with its flagship product Asceniv accounting for approximately 86% of total revenue, showcasing strong growth potential in the plasma-derived immunoglobulin market.
- EyePoint Pharmaceuticals Clinical Prospects: EyePoint Pharmaceuticals expects to announce top-line results for Duravyu soon, targeting wet age-related macular degeneration with a market opportunity exceeding $15 billion; analysts are overwhelmingly bullish, with a consensus price target 165% higher than the current share price.
- Viking Therapeutics Potential Breakthrough: Viking Therapeutics is conducting two Phase 3 trials for VK2735, and although it is currently unprofitable, its pipeline includes multiple promising therapies, with the average price target for the stock indicating a potential upside of 146%, reflecting significant growth potential.
See More
Surge in Protein Demand Strains U.S. Dairy Industry
- Dairy Shortages: The USDA reports that U.S. whey protein inventories have fallen by approximately 50% in 2023, leading to shortages among suppliers for the latter half of the year, indicating a tight market supply-demand situation.
- Price Surge: Whey protein isolate prices have reached $14 per pound, reflecting a spike in demand driven by the rising popularity of GLP-1 weight loss drugs, suggesting that protein consumption will continue to rise in the short term.
- Infrastructure Bottlenecks: As whey is a byproduct of cheese production, existing facilities cannot expand quickly, and the approval for additional filtration infrastructure can take years, limiting the supply chain's capacity to grow.
- Market Investment Opportunities: Major dairy companies like Dairy Farmers of America and Saputo are expected to be the first to increase capacity, and while current high prices may moderate in the coming years, it will take time for the market to adjust.
See More
